Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT Trial for Cervical Cancer Patients
NCT06866951Phase 3Withdrawn
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Cervical Cancer (CC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Planned start Mar 2025; status: withdrawn.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06866951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866951.